scholarly journals Comparative analysis of the arthroscopy efficacy and complex therapy in the treatment of degenerative meniscal tears in patients with knee osteoarthritis

2021 ◽  
Vol 5 (2) ◽  
pp. 71-77
Author(s):  
M.S. Bessarab ◽  
◽  
G.O. Krasnov ◽  
A.M. Charchyan ◽  
S.N. Khoroshkov ◽  
...  
Keyword(s):  
Comparative Analysis ◽  
Conservative Treatment ◽  
Knee Osteoarthritis ◽  
Chondroitin Sulfate ◽  
Treatment Satisfaction ◽  
Combined Treatment ◽  
Life Quality ◽  
Glucosamine Sulfate ◽  
Meniscal Tears ◽  
Complex Therapy

Aim: to evaluate the efficacy of conservative treatment in patients with degenerative meniscal tear (DMT) in the setting of knee osteoarthritis (OA) as an alternative to combined treatment. Patients and Methods: a prospective comparative study included 236 patients aged 45–65 years with DMT in the setting of stage I–III OA according to the Kellgren-Lawrence classification (70 of them — men). Group 1 consisted of 122 patients (86 of them — women) who underwent combined treatment: arthroscopy for DMT of the knee joint and complex therapy in the postoperative period: NSAIDs (celecoxib), a combined drug from the group of symptom-modifying slow-acting drugs SYSADOA (chondroitin sulfate + glucosamine sulfate), exercise therapy, physiotherapy. Group 2 (n=114) received only complex therapy. Control tests (pain assessment on the visual analog scale (VAS), WOMAC scale, life quality assessment on the EQ-5D scale, treatment satisfaction) were performed 10 and 20 weeks after the therapy initiation. Results: there was a statistically significant (p<0.05) improvement in VAS and WOMAC indicators, which continued to decline by week 20 after 10 weeks of both combined and conservative treatment. Also, it did not depend on gender, age, concomitant pathology, but on the body mass index and OA stage according to the Kellgren-Lawrence classification, which was confirmed by the results of the correlation analysis. Patients’ treatment satisfaction and improvement in their life quality were noted in 50% of patients in both groups. Conclusion: arthroscopic meniscectomy should not be indicated as the first treatment stage in patients with DMT during OA. Complex therapy, including the use of drugs from the NSAID and SYSADOA groups at the recommended doses, has demonstrated high treatment efficacy and safety of patients with DMT during OA. KEYWORDS: knee arthritis, degenerative meniscus tear, arthroscopy, celecoxib, chondroitin sulfate, glucosamine sulfate, life quality. FOR CITATION: Bessarab M.S., Krasnov G.O., Charchyan A.M., Khoroshkov S.N. et al. Comparative analysis of the arthroscopy efficacy and complex therapy in the treatment of degenerative meniscal tears in patients with knee osteoarthritis. Russian Medical Inquiry. 2021;5(2):71–77. DOI: 10.32364/2587-6821-2021-5-2-71-77.

EXPERIENCE OF CONSERVATIVE TREATMENT OF INTERVERTEBRAL DISC HERNIAS WITH CARIFLEX GEL AND CREAM IN AMBULATORY CONDITIONS

2020 ◽  
Vol 3 (1) ◽  
pp. 6-8
Author(s):  
Zufar ADAMBAEV ◽  
◽  
Ibodulla KILICHEV ◽  
Tuygunoy XODJANOVA
Keyword(s):  
Comparative Analysis ◽  
Conservative Treatment ◽  
Intervertebral Disc ◽  
Range Of Motion ◽  
Comparative Evaluation ◽  
Intervertebral Discs ◽  
Neurological Manifestations ◽  
Complex Therapy

A complex therapy of patients with degenerative-dystrophic diseases of the spine with herniated intervertebral discs with neurological manifestations was carried out with the addition of phonophoresis Kariflex gel followed by segmental massage with Kariflex cream. The comparative evaluation of the method was carried out in 89 patients. Comparative analysis revealed the reliable efficiency of the method used. Against the background of the proposed therapy, there was a significant decrease in pain and muscle-tonic syndromes, an increase in the range of motion in the spine

scholarly journals Chondroitin sulfate injection efficacy in the treatment of knee osteoarthritis

2021 ◽  
Vol 5 (5) ◽  
pp. 301-306
Author(s):  
S.A. Lapshina ◽  
◽  
G.F. Mingaleeva ◽  
Keyword(s):  
Knee Osteoarthritis ◽  
Chondroitin Sulfate ◽  
Matrix Protein ◽  
Life Quality ◽  
Pain Syndrome ◽  
Cartilage Degradation ◽  
Knee Joints ◽  
Standard Regimen ◽  
Reactive Protein ◽  
Keywords Osteoarthritis

Aim: to evaluate the efficacy of two-month therapy with chondroitin sulfate (CS) (Mucosat®) injections in patients with osteoarthritis and the drug potential in terms of structure-modifying action. Patients and Methods: an open prospective study with participation of 30 patients (mean age 52.5±11.7 years) with osteoarthritis, grade 2 gonarthrosis according to the Kellgren-Lawrence classification, and severe pain syndrome (more than 50 points according to VAS) was conducted. 76.7% of subjects had concomitant pathology. The drug was prescribed according to the standard regimen with a course of up to 25–30 injections. The examination included a clinical assessment of indicators of joint syndrome, life quality, joint function using WOMAC, Lekken, KOOS, EQ-5D scales, cartilage oligomeric matrix protein (COMP) and C-reactive protein (CRP), ultrasound of the knee joints. Results: after a two-month treatment course with Mucosat®, there was a significant (p<0.05) decrease in pain intensity by 1.8 times, the number of tender and swollen joints by 2 or more times, an improvement in indicators of functional activity and life quality of patients. Reactive synovitis of the knee joints, which was present at the beginning of the study in 53.3% of cases, was preserved clinically and according to ultrasound data only in 17% of subjects by the end of treatment. There was a tendency to decrease the levels of CRP and COMP. Ultrasound of the knee joints showed a significant (p=0.000) increase in the average thickness of articular cartilage from 1.55±0.26 mm initially to 1.67±0.27 mm after 2 months of treatment. More significant positive dynamics during therapy was observed in patients without arterial hypertension. In general, no adverse events were registered during treatment. Conclusion: in clinical practice, the use of the CS injections in patients with gonarthrosis is safe and effective. The tendency to decrease the cartilage degradation and increase its thickness suggests a positive effect of CS in the form of slowing the disease progression in the long-term period. KEYWORDS: osteoarthritis, cartilage degradation, synovitis, chondroitin sulfate, bioavailability, structure-modifying effect, Mucosat. FOR CITATION: Lapshina S.A., Mingaleeva G.F. Chondroitin sulfate injection efficacy in the treatment of knee osteoarthritis. Russian Medical Inquiry. 2021;5(5):301–306 (in Russ.). DOI: 10.32364/2587-6821-2021-5-5-301-306.

scholarly journals Treatment of knee osteoarthritis with a new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin: a multicenter, randomized, single-blind, non-inferiority clinical trial

2021 ◽  
Vol 61 (1) ◽  
Author(s):  
Andrea Barranjard Vannucci Lomonte ◽  
Emerson Gimenez ◽  
Antônio Carlos da Silva ◽  
Sebastião Cezar Radominski ◽  
Morton Aaron Scheinberg ◽  
...  
Keyword(s):  
Knee Osteoarthritis ◽  
Chondroitin Sulfate ◽  
Glucosamine Sulfate ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Womac Pain ◽  
Pain Subscale ◽  
Dose Combination ◽  
New Formulation ◽  
Single Blind

Abstract Objectives To compare the efficacy and safety of a new formulation of a fixed dose combination of glucosamine sulfate (GS; 1500 mg) and bovine chondroitin sulfate (CS; 1200 mg) versus the reference product (RP) in patients with knee osteoarthritis (OA). Methods In this multicenter, randomized, single-blind trial, 627 patients with knee osteoarthritis (OA)—Kellgren-Lawrence grades 2 or 3 and mean score ≥ 40 mm in the WOMAC pain subscale—were randomized to receive GS/CS or the RP for 24 weeks. The primary efficacy endpoint was the absolute change in WOMAC pain subscale score. The secondary endpoints included the following: WOMAC total and subscale scores, overall assessment of the disease by the patient and the investigator, SF-12 score, OMERACT-OARSI response rate to the treatment, and rescue medication use. Results Mean reductions of WOMAC pain score were − 35.1 (sd = 23.2) mm in the GS/CS group and − 36.5 (sd = 24.9) mm in the RP group. The difference between the adjusted means of both treatments confirmed the non-inferiority of GS/CS versus the RP. Improvement was observed in pain, stiffness, physical function and total WOMAC score, as well as in overall OA assessment by the patient and the investigator for both groups. No improvement was observed in SF-12. The rate of OMERACT-OARSI responders was 89.4% in GS/CS group and 87.9% in the RP group. Headache and changes in glucose tolerance were the most frequent treatment-related adverse events. Conclusions The new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin sulfate was non-inferior to the RP in symptomatic treatment of knee OA, with a high responder rate and good tolerability profile. Trial registration ClinicalTrials.gov; Registration number NCT02830919; Date of registration: July 13, 2016; First randomization date: December 05, 2016).

Sign in / Sign up

Export Citation Format

Share Document